Results 11 to 20 of about 7,079 (166)
Impact of vigabatrin on risk of relapse of infantile spasms. [PDF]
Epilepsia OpenAbstract Objective Vigabatrin is an effective treatment for infantile epileptic spasms syndrome (IESS), but relapse remains a clinical challenge. The ideal dose and duration of treatment after response are unknown. We set out to identify treatment‐related predictors of IESS relapse after initial vigabatrin response. Methods We conducted a retrospective
Carmenate YI +5 more
europepmc +3 more sources
Vigabatrin-Induced Visual Field Defects
Pediatric Neurology Briefs, 1998 A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 cases of symptomatic visual field defects associated with vigabatrin (usually as add-on therapy) between 1990 and 1997.
J Gordon Millichap
doaj +2 more sources
Vigabatrin-Associated Visual Field Defects
Pediatric Neurology Briefs, 2001 The prevalence, risk factors, and long-term outcome of vigabatrin-associated visual field defects were examined in 60 adult patients with partial epilepsy treated with vigabatrin for 7 months to 14 years at the University of Kuopio Hospital, Finland.
J Gordon Millichap
doaj +2 more sources
Vigabatrin-Associated “Acute Encephalopathy”
Pediatric Neurology Briefs, 2000 A 6-month-old girl with Alexander disease and hydrocephalus, treated at Children’s Hospital, Tubingen, Germany, developed acute encephalopathy within 3 days of starting vigabatrin (VGB).
J Gordon Millichap
doaj +2 more sources
Vigabatrin Intractable Epilepsy
Pediatric Neurology Briefs, 1992 The relationship between vigabatrin dosage and plasma concentrations, platelet GABA-transaminase inhibition and seizure reduction in 16 children with refractory epilepsy was studied at the University of Cantabria, Santander, Spain.
J Gordon Millichap
doaj +2 more sources
Vigabatrin for Infantile Spasms
Pediatric Neurology Briefs, 1999 The efficacy of vigabatrin (VGB) as the first, and adrenocorticotropin hormone (ACTH) or valproate (VPA) as the second, treatment of choice for newly diagnosed infantile spasms was evaluated in 42 infants treated at the University of Helsinki, Finland.
J Gordon Millichap
doaj +2 more sources
Long-term developmental outcome in infantile epileptic spasms syndrome after high-dose prednisolone and vigabatrin treatment. [PDF]
Epilepsia OpenAbstract Objective To evaluate long‐term developmental outcomes and identify independent predictors of favorable developmental outcomes at 3 years of age in children with infantile epileptic spasms syndrome (IESS) treated with a standardized stepwise vigabatrin and high‐dose prednisolone protocol.
Jang S +5 more
europepmc +2 more sources
Management of Infantile Epileptic Spasms Syndrome: A survey of US pediatric hospitals. [PDF]
Epilepsia OpenAbstract Objective To evaluate the management practices of Infantile Epileptic Spasms Syndrome (IESS) across tertiary pediatric hospitals in the United States using a survey‐based approach. Methods A 21‐question survey focused on management setting, work‐up, follow‐up and treatment was created and sent to 45 member institutions of the Pediatric ...
Katyayan A +16 more
europepmc +2 more sources
Ocular examinations, findings, and toxicity in children taking vigabatrin. [PDF]
, 2022 BACKGROUND: The antiepileptic medication vigabatrin has been associated with ocular toxicity, and close ophthalmic monitoring has been recommended; however, there is no clear consensus regarding the value and feasibility of such monitoring in children ...
Han, Ying +6 more
core +3 more sources
Diagnosis and management guidelines for infantile epileptic spasms syndrome around the world: A scoping review and comparative study of international approaches. [PDF]
EpilepsiaAbstract Objective Infantile epileptic spasms syndrome (IESS) is an epileptic encephalopathy requiring rapid diagnosis and treatment to optimize neurodevelopmental outcomes. Although multiple national and regional guidelines exist, recommendations vary.
Erdemir G +21 more
europepmc +2 more sources